Common Drug Review *

Submission Status

Product: Viread

Generic Name: tenofovir disoproxil fumarate

Manufacturer: Gilead Sciences Canada Inc.

Submission Type: New Indication

Date Submission Received: 2008-Oct-02 **Date NOC Issued:** 2008-Sep-03

Targeted CEDAC Meeting: 2009-Feb-18 **Priority Review Granted:** Not Requested

	Phase	Target Time (Business Days)	Target Date**	Actual CDR Date	Comments
1	Submission Assessment	5	2008-Oct-9	2008-Oct-09	Category 1 submission requirements deemed incomplete October 9, 2008.
	Submission deemed complete			2008-Oct-10	Submission deeemed complete.
2	CDR Reviewers' Reports Completed • Reviewers selected and contracted • Literature search and selection completed • Systematic review of clinical data completed • Critical appraisal of pharmacoeconomic (PE) data completed • Clinical and PE reports written • Reports edited and finalized • Reviewers' reports sent to manufacturer	45	2009-Jan-02	2009-Jan-05	Additional information requested October 22, 2008. Additional information received October 24, 2008. Additional information requested October 28, 2008. Additional information received October 29, 2008. Additional information requested November 14, 2008. Additional information received November 19, 2008. Additional information received November 24, 2008. Additional information requested November 27, 2008. Additional information received November 28, 2008. Additional information received December 3, 2008. Additional information received December 5, 2008.
3	Comments from Manufacturer on Reviewers' Reports Received by CDR	7	2009-Jan-13	2009-Jan-15	Due date for manufacturers' comments January 14, 2009.
4	Reviewers' Reply to Manufacturer's Comments Completed	7	2009-Jan-22	2009-Jan-26	Due date for reviewers' comments January 26, 2009.
5	CEDAC Brief Completed and Sent to CEDAC Members	5	2009-Feb-03	2009-Feb-03	Additional information requested February 11, 2009. Additional information received February 17, 2009.
6	CEDAC Meeting		2009-Feb-18	2009-Feb-18	
7	CEDAC Recommendation and Reasons for Recommendation Sent to Drug Plans, ACP and Manufacturer	5	2009-Feb-25	2009-Feb-25	
8	Embargo Period*** Manufacturers may make a Request for Reconsideration and Drug Plans may make a Request for Clarification of the Recommendation and Reasons for Recommendation	10	2009-Mar-11	2009-Mar-11	
9 (a)	Final Recommendation sent to Drug Plans, ACP, and Manufacturer (No Requests for Clarification are made AND no Request for Reconsideration is made or Request for Reconsideration is Resolved)	5	2009-Mar-18	2009-Mar-18	Notice of Final Recommendation issued.
	OR				
9 (b)	Clarification and Final Recommendation sent to Drug Plans, ACP, and Manufacturer (Clarification Requested, no Request for Reconsideration made)	5			
	OR				
9 (c)	Placed on CEDAC Agenda For Reconsideration (At Manufacturer's request)	25 Depends on Meeting Dates			
10	Final Recommendation sent to Drug Plans, ACP, and Manufacturer	5			

* Refer to the Procedure for Common Drug Review on the Common Drug Review section of www.cadth.ca for more details.

** The CDR review process is initiated AFTER a submission is deemed complete. The target dates for this report are based on the CEDAC meeting schedule, which is posted on www.cadth.ca.

*** The Recommendation and Reasons for Recommendation are to be held in confidence and not acted upon until after the CDR Directorate has issued the notice of Final Recommendation.

Reflects updates as of Thursday noon.